This is in partnership with Mepro Pharmaceuticals which have successfully developed and commercialised the Albendazole Chewable formulation
The emergence of new infections in India is a growing concern
This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
Based on AEGEAN Phase III trial results which showed Imfinzi-based regimen reduced the risk of recurrence, progression or death by 32% vs. neoadjuvant chemotherapy alone
The robotic surgery program has continually pushed the boundaries of medical technology
Becomes the first rehab & recovery center in east India to earn NABH accreditation
Majority of organizations are looking to increase investments in public and hybrid cloud
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
